Dylan V. Neel

Dylan V. Neel

Auto-generated profile, based on publicly available information

Dylan V. Neel

Sean M. Healey and AMG Center for ALS and the Neurological Clinical Research Institute, Massachusetts General Hospital Harvard Medical School Boston Massachusetts USA

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 March 2023 in Nature
Verified
Journal Article
Closed access
PDF file
FPFelipe A. Pinho-Ribeiro
Felipe A. Pinho-Ribeiro
LDLiwen Deng
Liwen Deng
DNDylan V. Neel
Dylan V. Neel
OEOzge Erdogan
Ozge Erdogan
HBHimanish Basu
Himanish Basu
ICIsaac M. Chiu
Isaac M. Chiu

20 December 2021 in Nature
Verified
Journal Article
Closed access
PDF file
LCLars E. Clark
Lars E. Clark
SCSarah A. Clark
Sarah A. Clark
CLChieYu Lin
ChieYu Lin
JLJianying Liu
Jianying Liu
ACAdrian Coscia
Adrian Coscia
JAJonathan Abraham
Jonathan Abraham

19 September 2022 in Drugs
Verified
Journal Article
Closed access
PDF file
SJStephen A. Johnson
Stephen A. Johnson
TFTon Fang
Ton Fang
FMFabiola De Marchi
Fabiola De Marchi
DNDylan Neel
Dylan Neel
DWDonatienne Mw. Van Weehaeghe
Donatienne Mw. Van Weehaeghe
SPSabrina Paganoni
Sabrina Paganoni

3 March 2025 in Nature Neuroscience
Verified
Journal Article
Closed access
PDF file
AKAtsushi Kadowaki
Atsushi Kadowaki
MWMichael Wheeler
Michael Wheeler
ZLZhaorong Li
Zhaorong Li
BABrian M. Andersen
Brian M. Andersen
HLHong-Gyun Lee
Hong-Gyun Lee
FQFrancisco J. Quintana
Francisco J. Quintana

7 May 2022 in Immunological Reviews
Verified
Journal Article
Closed access
DNDylan V. Neel
Dylan V. Neel
HBHimanish Basu
Himanish Basu
GGGeorgia Gunner
Georgia Gunner
ICIsaac M. Chiu
Isaac M. Chiu

18 September 2025 in European Journal of Neurology
Verified
Journal Article
Open access
NCNarghes Calcagno
Narghes Calcagno
ESErica Scirocco
Erica Scirocco
ECErin Clampffer
Erin Clampffer
GAGrace Addy
Grace Addy
SMSean Morgan
Sean Morgan
SPSabrina Paganoni
Sabrina Paganoni
Introduction/Aims: Sodium phenylbutyrate (PB) and taurursodiol (TURSO)—PB and TURSO—was approved as a treatment for amyotrophic lateral sclerosis (ALS) in the United States in 2022 based on the results of a phase 2 trial, but was voluntarily withdrawn from the market in 2024 after negative results from its phase 3 trial. The objective of our study was to describe the real‐world clinical experience with PB and TURSO at one ALS clinic.Methods: This was a retrospective chart review of all ALS patients receiving a PB and TURSO prescription at the Massachusetts General Hospital ALS Clinic between October 1, 2022, and September 30, 2023. Data were extracted from patients' electronical medical records up to December 31, 2023.Results: A total of 441 ALS patients received a PB and TURSO prescription, with 329 (75%) initiating the medication. The average length of treatment was 285 days, and the rate of drug discontinuation during the study period was 41% (N=135). The most common reason for drug discontinuation was side effects (N=93, 69%), with the most common being gastrointestinal issues (N=69). No hospitalizations, deaths, or serious adverse events were considered related to treatment with PB and TURSO.Discussion: Experience in real‐world clinical settings can help supplement trial data with information on the drug performance at various stages of disease progression. Adverse events impacted treatment persistence in routine clinical practice, underscoring the need for vigilant monitoring and tailored supportive interventions to optimize treatment adherence.